MET-PA — MetLife, Inc.

MetLife Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Earnings: $1.6 billion, or $2.34 per share (up 21% year-over-year).
• Net Income: Adjusted earnings included notable items totaling $18 million, resulting in a net adjusted earnings per share of $2.37.
• Variable Investment Income: $483 million, exceeding guidance of $425 million, driven by strong private equity returns (3%).
• Return on Equity: 16.7%, aligning with the target range of 15% to 17%.
• Direct Expense Ratio: 11.6%, below the full-year target of 12.1%.
• Shareholder Returns: Approximately $875 million returned to shareholders through dividends and share repurchases in Q3.

2. Strategic Updates and Business Highlights

• New Frontier Strategy: Continued positive impact on diversified business segments, notably in Group Benefits and Retirement Income Solutions (RIS).
• Group Benefits: Adjusted earnings of $457 million (up 6%), with improved underwriting results and a 230 basis point sequential improvement in the nonmedical health loss ratio.
• Retirement and Income Solutions: Adjusted earnings of $423 million (up 15%), with strong performance from variable investment income and a successful launch of Chariot Re, facilitating a $10 billion reinsurance transaction.
• Asia Performance: Adjusted earnings of $473 million (up 36%), with sales growth of 34% driven by new product launches in Japan and strong performance in Korea and China.
• Latin America: Adjusted earnings of $222 million (up 2%), with continued business momentum and a partnership with MercadoLibre enhancing the digital platform.
• EMEA: Adjusted earnings of $89 million (up 19%), primarily due to volume growth.

3. Forward Guidance and Outlook

• Pension Risk Transfer (PRT): Anticipated record performance in Q4 with $12 billion already secured in PRT transactions.
• Expense Management: Expected to remain below the target ratio, with continued efficiency gains from technology investments.
• Long-term Growth: Positive outlook for PRT business and overall growth trajectory, with expectations to exceed full-year sales guidance for 2025.

4. Bad News, Challenges, or Points of Concern

• Tax Law Impact in Mexico: A notable charge related to a change in VAT deductions for health insurance claims, expected to reduce adjusted earnings by $50 million to $60 million in 2026.
• Group Benefits Underwriting: Group life mortality ratio at 83.3%, below the target range, indicating potential challenges in underwriting performance.
• Market Competition: Competitive pressures in the Group Benefits market, although described as rationally priced, could impact future growth.

5. Notable Q&A Insights

• Asia Sales Strength: Key drivers include successful product launches and enhancements, particularly in Japan, with expectations for continued momentum.
• PRT Market Dynamics: The record quarter for PRT was attributed to large deals and MetLife's strong balance sheet and investment capabilities.
• Expense Seasonality: Anticipated higher expenses in Q4 but expected to remain below the target ratio due to disciplined management and technology-driven efficiencies.
• Private Credit Concerns: MetLife emphasized its disciplined underwriting approach and high-quality asset management in response to market commentary on private credit risks.

This summary encapsulates the key points from MetLife's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, and outlook while addressing potential challenges and insights from the Q&A session.